In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3537-3537
Abstract:
Introduction: An elevated concentration of serum cobalamin was found in one third of patients with acute myeloid leukemia; however, the clinical implication of elevated level of cobalamin in disease prognosis is not clear. Procedures: We performed a retrospective analysis of the patients who were diagnosed to have de novo acute myeloid leukemia at China Medical University Hospital from January 2003 to December 2011. Two hundred and six patients were diagnosed as de novo acute myeloid leukemia, and thirty-four patients (16.5%) had been checked the level of serum cobalamin at diagnosis. Patients were divided into two groups, one with serum cobalamin level less than 400 pg/mL (n=10), the other with serum cobalamin level 400 pg/mL or higher (n=24). The clinical and cytogenetic characteristics between each group were compared. Findings: There was no difference in gender, age and cytogenetic risk between the two groups. Nine of ten patients in lower serum cobalamin group and eighteen of twenty-four patients in higher serum cobalamin group received intensive chemotherapy for acute myeloid leukemia (p=0.315). The patients with lower serum cobalamin had a trend to obtain complete remission (80.0 % vs. 45.8 %, p=0.072). For patients who reached complete remission after chemotherapy, those in the higher cobalamin group had a trend to have more disease relapse (81.8% vs. 37.5%, p=0.067). Interestingly, the relapse-free survival time after complete remission was 42.5 m and 9.2 m for patients with lower and higher cobalamin, respectively (p=0.010). Furthermore, serum cobalamin level remained significant in the multivariate analysis of risk factors for relapse-free survival (p=0.028). The median overall survival time was 18.3 m and 7.2 m for patients with lower and higher cobalamin, respectively. However, the difference in overall survival between the two groups did not reach statistical significance (p=0.140). In multivariate analysis, intensive chemotherapy for AML was the most important factor for overall survival. Conclusions: AML patients with higher serum level of cobalamin have a trend of worse response to chemotherapy, higher relapse rate and significantly shorter relapse-free survival time. Targeted therapy to interfere the cobalamin uptake or related pathways is worth of further investigation in treating patient with acute myeloid leukemia. Citation Format: Li-Yuan Bai, Tzu-Ting Chen, Long-Yuan Li, Chang-Fang Chiu. Serum cobalamin level and clinical outcome in patients with acute myeloid leukemia. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3537. doi:10.1158/1538-7445.AM2013-3537
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2013-3537
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2013
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Bookmarklink